Regeneron (REGN) Halted Ahead of FDA Panel Review of Praluent

(Updated - June 9, 2015 7:05 AM EDT)

Regeneron (NASDAQ: REGN) trading halted with news pending.

UPDATE - The halt comes ahead of the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee, which will review Regeneron and Sanofi's PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody, Praluent.

BMO Capital recently commented on the matter here, and RBC Capital commented here.

You May Also Be Interested In

• FDA approves Regeneron's Pasatru for rare bone disorder FOP
• BMO Capital Starts Marvell (MRVL) at Outperform
• Regeneron Announces Investor Conference Presentations